Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BLM | P54132 | 1/20 | 1.00 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.59 |
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
| ▸ | GABRR1 | P24046 | 2/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | LTA4H | P09960 | 1/20 | 0.47 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.38 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.38 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26624410 | 1.00 | BLM (1.00) | BLMACE2LMNAGABRR1CYP1A2 | |
| SCHEMBL11600716 | 1.00 | BLM (1.00) | BLMACE2LMNAGABRR1CYP1A2 | |
| SCHEMBL23673151 | 0.96 | BLM (0.92) | BLMACE2LMNAGABRR1CYP1A2 | |
| SCHEMBL5879073 | 0.95 | BLM (0.91) | BLMACE2LMNAGABRR1CYP1A2 | |
| SCHEMBL276749 | 0.93 | BLM (0.86) | BLMACE2LMNAGABRR1CYP1A2 | |
| SCHEMBL6254815 | 0.93 | BLM (0.86) | BLMACE2LMNAGABRR1CYP1A2 | |
| SCHEMBL6249628 | 0.93 | BLM (0.86) | BLMACE2LMNAGABRR1CYP1A2 | |
| SCHEMBL27489073 | 0.91 | BLM (0.83) | BLMACE2LMNAGABRR1CYP1A2 | |
| SCHEMBL11879730 | 0.91 | BLM (0.83) | BLMACE2LMNAGABRR1CYP1A2 | |
| SCHEMBL13343956 | 0.88 | BLM (0.78) | BLMACE2LMNAGABRR1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1481 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3795187-B1 | COATING FOR INTRALUMINAL EXPANDABLE CATHETER PROVIDING CONTACT TRANSFER OF DRUG MICRO-RESERVOIRS | M A MED ALLIANCE SA (CH) | 2026-03-11 | — | — | EP | claimed |
| US-20250174445-A1 | MASS SPECTROMETRIC DETERMINATION OF FATTY ACIDS | QUEST DIAGNOSTICS INVEST LLC (US) | 2025-05-29 | — | — | US | claimed |
| CN-119162094-B | Serum-free method for inducing fish muscle stem cells to undergo lipogenic transdifferentiation and application thereof | 中国海洋大学 | 2025-03-18 | — | — | CN | claimed |
| EP-4490270-A1 | NOVEL METHOD FOR DIFFERENTIATING ADULT STEM CELLS INTO FINAL | Innocent Meat GmbH (DE) | 2025-01-15 | — | — | EP | claimed |
| CN-119207584-A | Computer-implemented method for evaluating plant nitrogen absorption capacity through rhizosphere soil environmental characteristics | 贵州省蚕业研究所(贵州省辣椒研究所) | 2024-12-27 | — | — | CN | claimed |
| CN-119162094-A | Serum-free method for inducing fish muscle stem cells to undergo lipogenic transdifferentiation and application thereof | 中国海洋大学 | 2024-12-20 | — | — | CN | claimed |
| CN-119125356-A | Method and kit for measuring various free fatty acids in body fluid by liquid chromatography-tandem mass spectrometry | 杭州博圣医学检验实验室有限公司 | 2024-12-13 | — | — | CN | claimed |
| US-20240117313-A1 | METHOD FOR PRODUCING THREE-DIMENSIONAL TISSUE BODY AND METHOD FOR PROMOTING DIFFERENTIATION OF ADIPOSE-DERIVED STEM CELLS | TOPPAN INC. (JP) | 2024-04-11 | — | — | US | claimed |
| US-20240047186-A1 | MASS SPECTROMETRIC DETERMINATION OF FATTY ACIDS | QUEST DIAGNOSTICS INVESTMENTS INCORPORATED | 2024-02-08 | — | — | US | claimed |
| US-20240002806-A1 | METHOD FOR DIFFERENTIATING ADULT STEM CELLS INTO FINAL TISSUE | Innocent Meat GmbH (DE) | 2024-01-04 | — | — | US | claimed |
| JP-2004531543-A | — | — | 2004-10-14 | — | — | JP | claimed |
| WO-2004064761-A2 | THERAPEUTICALLY ACTIVE COMPOUNDS | ENCORE PHARMACEUTICALS, INC. (US) | 2004-08-05 | — | — | WO | claimed |
| US-20040152146-A1 | Methods for screening compounds for use in the treatment of disease | ENCORE PHARMACEUTICALS, INC. | 2004-08-05 | — | — | US | claimed |
| WO-2004064539-A2 | FAT SUBSTITUTES | ENCORE PHARMACEUTICALS, INC. (US) | 2004-08-05 | — | — | WO | claimed |
| WO-2004062389-A1 | PREPARATIONS CONTAINING POLYUNSATURATED PHOSPHOLIPIDS, MONOTERPENES AND OPTIONALLY TRYPTOPHAN AND/OR PHYTOL DERIVATIVES | HUNZA DI PISTOLESI ELVIRA & C. S.A.S. (IT) | 2004-07-29 | — | — | WO | claimed |
| WO-2004055200-A2 | METHODS FOR SCREENING COMPOUNDS FOR USE IN THE TREATMENT OF DISEASE | ENCORE PHARMACEUTICALS, INC. (US) | 2004-07-01 | — | — | WO | claimed |
| US-20040121979-A1 | Pharmaceutically active uridine esters | TROMMSDORFF GMBH & CO. KG ARZNEIMITTEL (DE) | 2004-06-24 | — | — | US | claimed |
| CN-1505636-A | Pharmaceutically active uridine esters | ����ķ˹�ลҩ���ɷ�����˾������ | 2004-06-16 | — | — | CN | claimed |
| EP-1390378-A1 | PHARMACEUTICALLY ACTIVE URIDINE ESTERS | Trommsdorff GmbH & Co. KG Arzneimittel (DE) | 2004-02-25 | — | — | EP | claimed |
| WO-2002088159-A1 | PHARMACEUTICALLY ACTIVE URIDINE ESTERS | TROMMSDORFF GMBH & CO. KG ARZNEIMITTEL (DE) | 2002-11-07 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040121979-A1 | Pharmaceutically active uridine esters | UMPS, UGDH, FFAR1 | BLM 3727/4885ACE2 3502/4885LMNA 2730/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.